On-going Phase 3 Clinical Program of Simufilam Cassava Sciences is evaluating oral simufilam for Alzheimer's disease dementia in two global, randomized, double-blind, placebo-controlled Phase 3 clinical studies. Both Phase 3 studies have received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration. Our first Phase 3 trial has a 12-month treatment period and has enrolled 804 patients with mild-to-moderate Alzheimer's disease who also meet other study eligibility criteria.